FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377029441> ?p ?o ?g. }

• W4377029441 abstract "<b>Abstract ID 28360</b> <b>Poster Board 243</b> High-risk neuroblastoma (NB) is a solid pediatric tumor that develops from the extracranial sympathetic nervous system. Despite recent advances in therapeutic regimens of dose-intensive chemotherapies, radiation, and surgery NB often relapses as a metastatic and drug-resistant tumor. These issues further mandate the identification and development of novel therapeutic approaches for NB treatment. Cell cycle regulators, Cdk1 in combination with cyclin B1, and Cdk2 with cyclin E regulate the G2/M checkpoint and G1/S checkpoint respectively, to obstruct the cells from proceeding into mitosis with genomic DNA damage. Wee1, a tyrosine kinase, regulates the phosphorylation of Cdk1 and Cdk2 at tyrosine residues in response to DNA damage, making them inactive. Previous studies have reported high expression of Wee1 in NB patients and associate Wee1 with an overall poor NB prognosis. Inhibition of Wee1 obstructs the Cdk1 and Cdk2 activation and is no more reliant on an intact G2/M checkpoint for survival. In the present study, we analyzed multiple NB patient datasets and found that Wee1 expression is strongly correlated with poor overall survival of NB patients. Further, we used a specific small molecule Wee1 inhibitor in NB cells and observed that Wee1 inhibition significantly and in a dose-dependent manner inhibits NB proliferation and colony formation capacity in both MYCN-amplified and MYCN non-amplified NB cells. Further, Wee1 inhibition significantly induces apoptosis up to 3-fold in different NB cells in contrast to control treatments. Additionally, we used NB 3D spheroid models that mimic <i>in vivo</i> NB tumor growth and found that Wee1 inhibition significantly and in a dose-dependent manner inhibits 3D spheroid growth and volume up to 2.3-fold in contrast to control treatments. Additionally, and as expected, inhibition of Wee1 significantly inhibits NB cell cycle progression by inhibiting cell cycle S phase and blocking G2/M checkpoint in different NB cell lines. Further, the Wee1 inhibition inhibits the gene expression levels of different cell cycle-related genes in NB cells such as CDK1, CDK2, CCNB1, CHK2, and BCL-2. Overall, our data suggest that inhibition of the cell cycle regulator Wee1 is an effective therapeutic approach for NB. Further combining Wee1 inhibitors with current therapies will pave the way for developing effective targeted therapeutic approaches for NB patients. Support/Funding Information: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John9s University, New York" @default.
• W4377029441 created "2023-05-19" @default.
• W4377029441 creator A5040706261 @default.
• W4377029441 creator A5040858700 @default.
• W4377029441 creator A5060377718 @default.
• W4377029441 date "2023-05-18" @default.
• W4377029441 modified "2023-09-29" @default.
• W4377029441 title "Direct Targeting of the Cell cycle Regulator<i>WEE1</i>is a Novel Therapeutic Approach for Neuroblastoma" @default.
• W4377029441 doi "https://doi.org/10.1124/jpet.122.283600" @default.
• W4377029441 hasPublicationYear "2023" @default.
• W4377029441 type Work @default.
• W4377029441 citedByCount "0" @default.
• W4377029441 crossrefType "proceedings-article" @default.
• W4377029441 hasAuthorship W4377029441A5040706261 @default.
• W4377029441 hasAuthorship W4377029441A5040858700 @default.
• W4377029441 hasAuthorship W4377029441A5060377718 @default.
• W4377029441 hasBestOaLocation W43770294411 @default.
• W4377029441 hasConcept C105696609 @default.
• W4377029441 hasConcept C120504264 @default.
• W4377029441 hasConcept C190283241 @default.
• W4377029441 hasConcept C2776715637 @default.
• W4377029441 hasConcept C2778583388 @default.
• W4377029441 hasConcept C2781252693 @default.
• W4377029441 hasConcept C29537977 @default.
• W4377029441 hasConcept C50001416 @default.
• W4377029441 hasConcept C502942594 @default.
• W4377029441 hasConcept C54355233 @default.
• W4377029441 hasConcept C81885089 @default.
• W4377029441 hasConcept C82495950 @default.
• W4377029441 hasConcept C86803240 @default.
• W4377029441 hasConcept C95444343 @default.
• W4377029441 hasConceptScore W4377029441C105696609 @default.
• W4377029441 hasConceptScore W4377029441C120504264 @default.
• W4377029441 hasConceptScore W4377029441C190283241 @default.
• W4377029441 hasConceptScore W4377029441C2776715637 @default.
• W4377029441 hasConceptScore W4377029441C2778583388 @default.
• W4377029441 hasConceptScore W4377029441C2781252693 @default.
• W4377029441 hasConceptScore W4377029441C29537977 @default.
• W4377029441 hasConceptScore W4377029441C50001416 @default.
• W4377029441 hasConceptScore W4377029441C502942594 @default.
• W4377029441 hasConceptScore W4377029441C54355233 @default.
• W4377029441 hasConceptScore W4377029441C81885089 @default.
• W4377029441 hasConceptScore W4377029441C82495950 @default.
• W4377029441 hasConceptScore W4377029441C86803240 @default.
• W4377029441 hasConceptScore W4377029441C95444343 @default.
• W4377029441 hasLocation W43770294411 @default.
• W4377029441 hasOpenAccess W4377029441 @default.
• W4377029441 hasPrimaryLocation W43770294411 @default.
• W4377029441 hasRelatedWork W1969308341 @default.
• W4377029441 hasRelatedWork W1996347498 @default.
• W4377029441 hasRelatedWork W2010683612 @default.
• W4377029441 hasRelatedWork W2033424921 @default.
• W4377029441 hasRelatedWork W2094832062 @default.
• W4377029441 hasRelatedWork W2119460775 @default.
• W4377029441 hasRelatedWork W2415167083 @default.
• W4377029441 hasRelatedWork W2549574514 @default.
• W4377029441 hasRelatedWork W3032920186 @default.
• W4377029441 hasRelatedWork W4377029441 @default.
• W4377029441 isParatext "false" @default.
• W4377029441 isRetracted "false" @default.
• W4377029441 workType "article" @default.